pDONR223-ERBB3 Citations (9)
Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Nov 24. ():. PubMed Journal
Articles Citing pDONR223-ERBB3
| Articles |
|---|
| HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. Safavi S, Jarnum S, Vannas C, Udhane S, Jonasson E, Tomic TT, Grundevik P, Fagman H, Hansson M, Kalender Z, Jauhiainen A, Dolatabadi S, Stratford EW, Myklebost O, Eriksson M, Stenman G, Stock RS, Stahlberg A, Aman P. Oncotarget. 2015 Nov 16. doi: 10.18632/oncotarget.6336. PubMed |
A MultiSite Gateway Toolkit for Rapid Cloning of Vertebrate Expression Constructs with Diverse Research Applications.
Fowler DK, Stewart S, Seredick S, Eisen JS, Stankunas K, Washbourne P.
PLoS One. 2016 Aug 8;11(8):e0159277. doi: 10.1371/journal.pone.0159277. eCollection 2016.
PubMed
Associated Plasmids |
| Human papillomavirus regulates HER3 expression in head and neck cancer: implications for targeted HER3 therapy in HPV(+) patients. Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RC, Johnson DE, Grandis JR. Clin Cancer Res. 2016 Dec 16. pii: clincanres.2203.2016. doi: 10.1158/1078-0432.CCR-16-2203. PubMed |
| Multiplexed Exchange-PAINT imaging reveals ligand-dependent EGFR and Met interactions in the plasma membrane. Werbin JL, Avendano MS, Becker V, Jungmann R, Yin P, Danuser G, Sorger PK. Sci Rep. 2017 Sep 22;7(1):12150. doi: 10.1038/s41598-017-12257-y. PubMed |
| Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR. Cancer Res. 2018 May 1;78(9):2383-2395. doi: 10.1158/0008-5472.CAN-17-1672. Epub 2018 Feb 12. PubMed |
| Delete_A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance. Al-Akhrass H, Conway JRW, Poulsen ASA, Paatero I, Kaivola J, Padzik A, Andersen OM, Ivaska J. Oncogene. 2021 Feb;40(7):1300-1317. doi: 10.1038/s41388-020-01604-5. Epub 2021 Jan 8. PubMed |
| Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. Campbell MR, Ruiz-Saenz A, Peterson E, Agnew C, Ayaz P, Garfinkle S, Littlefield P, Steri V, Oeffinger J, Sampang M, Shan Y, Shaw DE, Jura N, Moasser MM. Cell Rep. 2022 Feb 1;38(5):110291. doi: 10.1016/j.celrep.2021.110291. PubMed |
| Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM. Cell Rep. 2022 Feb 1;38(5):110285. doi: 10.1016/j.celrep.2021.110285. PubMed |
| Met-HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells. Stern YE, Al-Ghabkari A, Monast A, Fiset B, Aboualizadeh F, Yao Z, Stagljar I, Walsh LA, Duhamel S, Park M. Cell Mol Life Sci. 2022 Mar 5;79(3):178. doi: 10.1007/s00018-022-04149-w. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.